Platelet-activating factor antagonists as therapeutic strategy in sepsis.
Dhainaut
J F
JF
Medical ICU, Cochin Port-Royal University Hospital, Paris, France.
Mira
J P
JP
Brunet
F
F
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004224:Diterpenes; D004731:Endotoxins / Q000633:toxicity; D046934:Ginkgolides; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D018805:Sepsis / Q000188:drug therapy* / Q000503:physiopathology; D012772:Shock, Septic / Q000188:drug therapy
D004224:Diterpenes; D004731:Endotoxins; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; C045856:ginkgolide B